Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Moderna Spotlights Lung Delivery As One Of Its mRNA 'Dreams'

Program With Vertex Highlighted At Science And Technology Day

Executive Summary

The company’s emphasis on artificial intelligence has played a leading role in development of lipid nanoparticles enabling delivery of mRNA to lung tissue under a partnership with Vertex.

You may also be interested in...



BioNTech On The Evolving COVID-19 Vaccine Strategy

The path for developing a variant-adapted COVID-19 vaccine remains uncertain, but the company expects to have more clarity following an FDA advisory committee meeting in June.

As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance

Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.

Moderna Teases M&A Interest As Pandemic Expected To Wind Down

Spikevax revenues beat expectations but analysts are bracing for the eventuality of lower vaccine revenues as COVID-19 becomes endemic. Moderna will have four new vaccines in Phase III this quarter.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel